


eISBN: 978-1-68108-231-8
ISBN: 978-1-68108-232-5

eISSN: 2214-5168
ISSN: 2451-8743

Frontiers in Clinical Drug Research (Alzheimer Disorders)

Volume 5



Editor:
Atta-ur-Rahman, *FRS*

Bentham  Books

**Frontiers in Clinical Drug
Research
Alzheimer Disorder
(*Volume 5*)**

Edited By

Atta-ur-Rahman, *FRS*

Kings College

University of Cambridge

Cambridge

UK

Frontiers in Clinical Drug Research - Alzheimer Disorders

Volume #5

ISSN (Online): 2214-5168

ISSN (Print): 2451-8743

Editors/Authors: Prof. Atta-ur-Rahman, *FRS*

ISBN (Online): 978-1-68108-231-8

ISBN (Print): 978-1-68108-232-5

©2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2016.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.org



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iii
CHAPTER 1 SHOULD PHYSICIANS SCREEN FOR DEMENTIA IN THE PRIMARY CARE SETTING?	3
<i>RcwiFcxlf "Fcu j</i>	
INTRODUCTION	3
SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?	5
Considerations in Screening for a Disease	5
<i>Does Dementia Pass Muster as a Disease Worthy of Screening?</i>	6
<i>CRITERION 1: How Prevalent and Costly is Alzheimer's disease?</i>	6
<i>CRITERION 2: Are Early Stages of Dementia not Obvious?</i>	6
<i>CRITERION 3: Are Screening Tools Cheap and Effective?</i>	7
<i>CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening?</i>	7
<i>Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference?</i>	10
Potential Non-Disease Indirect Benefits of Screening for Dementia	11
<i>Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems</i>	11
<i>Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium</i>	12
<i>Potential Benefit of Early Detection #3: Additional Time for Family Planning</i>	13
<i>Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances</i>	14
<i>Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too late</i>	14
<i>Potential Benefit #6—Identification of Potentially Reversible Dementias—and Reversing Them</i>	15
<i>Potential Benefit #7: Identification of Patients for Research Program Participation</i>	16
<i>Potential Benefit #8: Establishment of a Cognitive Baseline</i>	17
The Key Question: Can Earlier Intervention in Dementia Make a Difference?	18
SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING	20
The Mini-Mental State [44]	24
Montreal Cognitive Assessment (MoCA) [47]	25
The Clock Draw Test	26
The Mini-Cog [58]	27
Buschke's Memory Impairment Screen [61]	27
Semantic and Lexical Fluency Tasks as Screening Tools	27
The Hopkins Verbal Learning Test (HVLT) [71]	29
The Q&E (Quick and Easy)	29
CONCLUSION	33
NOTES	34
CONFLICT OF INTEREST	34
ACKNOWLEDGEMENTS	34
REFERENCES	34
CHAPTER 2 ENDOTHELIAL DYSFUNCTION AND CHRONIC LOW-GRADE INFLAMMATION AS POTENTIAL THERAPEUTIC TARGETS IN DEMENTIA DISORDERS	41
<i>Cidlc \ celt ci le. 'P gu lpc 'Cxf ci le. 'P gt o lpc 'Dcdle. 'Co gr 'F gx l g x l e. 'Co lpc 'Xcrl g x c e. 'Cro lt 'Hc l m k e. "</i> <i>Lc u o l p m q "J w u n k e. "Cro k t c "J c f q x l e / F w x q 'c p f "Q t j c p "N g r c t c</i>	
INTRODUCTION	42

The designed cover image is created by Bentham Science and Bentham Science holds the copyrights for the image

Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia	46
<i>Endothelial Dysfunction and Dementia</i>	50
Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia Disorders	61
<i>Endothelin Receptor Antagonists</i>	61
Anti-Inflammatory Drugs	63
<i>Nonsteroidal Anti-Inflammatory Drugs</i>	63
<i>Cytokine Suppressive Anti-Inflammatory Drugs</i>	65
CONCLUSION	67
ACKNOWLEDGEMENTS	68
CONFLICT OF INTEREST	68
REFERENCES	68
CHAPTER 3 RECENT CLINICAL DEVELOPMENTS IN ALZHEIMER'S DISEASE	83
<i>Zkp'I kEj qq'cpf 'Crgzcpf tc'I twdo cp</i>	
INTRODUCTION	83
Therapeutic Strategies and Clinical Trials	85
<i>Cholinergic Hypothesis</i>	85
<i>Amyloid Cascade Hypothesis</i>	89
<i>Inflammation in AD</i>	99
<i>Metal Dyshomeostasis in AD</i>	103
Future Development: Challenges and Recent Advances	108
CONFLICT OF INTEREST	112
ACKNOWLEDGEMENTS	112
ABBREVIATIONS	112
REFERENCES	114
CHAPTER 4 RECENT PERSPECTIVE ABOUT THE AMYLOID CASCADE HYPOTHESIS AND STEM CELL-BASED THERAPY IN THE TREATMENT OF ALZHEIMER'S DISEASE	144
<i>J cp{ 'G00 ctgk 'Cuo ce 'Cnj cpk 'Lcpc 'Uj qgp. 'Oqj co gf 'G0Gn\ qy cixf. 'Oqj co o cf 'C0Crdcpc.</i>	
<i>'Ectnq'Egpekt gnk'Vgpi lqk'Y cpi 'cpf 'Vj qo cu'Ecegek</i>	
ALZHEIMER'S DISEASE PATHOPHYSIOLOGY	145
GENERAL VIEW ABOUT AD	146
GENETIC BASIS OF AD AND AMYLOID CASCADE THEORY	148
The Amyloid Cascade Hypothesis	150
Argument Against the Amyloid Cascade Hypothesis	151
Stem Cell-Based Therapy for AD	154
Neural Stem Cell-Based Therapy for AD	154
Induced Pluripotent Stem Cell-Based Therapy for AD	158
Expert View and Future Perspectives	160
CONFLICT OF INTEREST	161
ACKNOWLEDGEMENTS	161
REFERENCES	162
CHAPTER 5 CURRENT CONCEPTS IN MANAGEMENT OF ALZHEIMER'S DISEASE	175
<i>Xlf c'F go ctkp. \ rnuq'Vineplge. 'O ctklcpc 'Dqurct 'Rwt gvk . 'U:pf tc 'O qt qxx 'cpf 'Cpxqp'I rnuqxxk</i>	
INTRODUCTION	176
EPIDEMIOLOGY	176
SYMPTOMS AND DISEASE COURSE	177
Early Stage	177
Moderate Stage	177
Advanced Stage	178
DISEASE CAUSES AND MECHANISMS	178
Genetics	178

Cholinergic Hypothesis	179
Amyloid Hypothesis	179
Tau Hypothesis	180
Other Hypotheses	180
NEUROPATHOLOGY	182
BIOCHEMISTRY	182
DISEASE MECHANISMS	182
DIAGNOSIS	183
Early Diagnosis	185
PREVENTION	185
MANAGEMENT	186
Medications	187
Psychosocial Intervention	188
Caregiving	189
PROGNOSIS	189
SOCIOECONOMIC BURDEN	190
Caregiving Burden	190
TREATMENTS UNDER RESEARCH	190
MILD COGNITIVE IMPAIRMENT	192
Diagnosis	193
Treatment	193
CONCLUSION	194
CONFLICT OF INTEREST	195
ACKNOWLEDGEMENTS	195
REFERENCES	195

CHAPTER 6 NATURAL COMPOUNDS FROM PLANTS TARGETING ALZHEIMER'S DISEASE ... 214

Cpf t gk 'Eqt ekqxc. 'F cplgrc 'O cvgk 'Ectkp 'Eqt ekqxc 'cpf 'Dkpec 'K pguew

INTRODUCTION	215
PATHOPHYSIOLOGICAL MECHANISMS	216
Beta-Amyloid and Tau Proteins	216
Neurotransmitters	217
Hypothalamic-Pituitary-Adrenal Axis	218
Oxidative Stress	218
Inflammation	219
Metal Hypothesis	221
Endothelial Dysfunction	221
Insulin Dysfunctions	224
NATURAL PRODUCTS	227
Vitis vinifera	227
Punica granatum L	230
Curcuma longa	233
Camellia sinensis	236
Olea europaea	239
Salvia miltiorrhiza	242
Ginkgo biloba	245
Melissa Officinalis	247
METHODS FOR ANALYSIS OF BIOACTIVE COMPOUNDS	251
Sample Preparation	256
Overview of Extraction Methods	257
<i>Phenolic Acids and Tannins Extraction</i>	259
<i>Stilbenes Extraction</i>	260

3.2.3. <i>Curcuminoids Extraction</i>	261
<i>Catechins Extraction</i>	261
<i>Triterpenes Extraction</i>	262
<i>Lactones Extraction</i>	263
Quantification of Bioactive Compounds	263
<i>Phenolic Acids and Tannins Quantification</i>	264
<i>Stilbenes Quantification</i>	269
<i>Curcuminoids Quantification</i>	269
<i>Catechines Quantification</i>	273
<i>Triterpenes Quantification</i>	274
<i>Lactones Quantification</i>	275
CONCLUSION	276
CONFLICT OF INTEREST	277
ACKNOWLEDGEMENTS	278
REFERENCES	278
SUBJECT INDEX	303

PREFACE

The book series, “*Frontiers in Clinical Drug Research – Alzheimer Disorders*” presents some important advancements in the field in the form of cutting edge reviews written by eminent experts.

Chapter 1 by Paul David Dash discusses the significant impact of cognitive impairment on a number of clinical matters. The author briefly explains the pros and cons of some of the numerous cognitive screens that can be utilized for screening purposes.

Chapter 2 Zaciragic *et al.* discuss the detrimental vascular changes that lead to consequent amyloid- β accumulation. This in turn leads to dementia. Moreover it provides a comprehensive insight into currently available evidence on molecular pathways and factors implicated in the above mechanisms. The findings from ongoing clinical trials and results from studies using novel pharmacological approaches to target endothelial dysfunction and chronic low-grade inflammation as pathophysiological events that contribute to the onset and development of dementia disorders are summarized.

Choo & Grubman in chapter 3 present an update on the prevailing mechanistic hypotheses, to explain AD pathogenesis, including the cholinergic, amyloid-cascade, inflammatory and metal dyshomeostasis theories. They present the recent clinical developments in therapies targeting each of the hypotheses, and highlight promising areas requiring further attention.

In chapter 4, Mareii *et al.* highlight the recent thinking against the long standing amyloid cascade hypothesis as well as the major efforts in the experimental application of stem cell based therapies used as treatment options for AD. Demarin *et al.*, in chapter 5 emphasize on the early disease detection and delaying cognitive impairment via various lifestyle modifications.

In chapter 6, Matei *et al.* present the methods of extraction, identification and quantification of the active compounds from various vegetal products *e.g.* curcuminoids, ellagic acid, gallic acid, salvianolic acid B, resveratrol and epigallocatechin-3-gallate that can target the causative agent of Alzheimer’s disease.

The 5th volume of this book series represents the results of a huge amount of work by many eminent researchers. I am grateful to the authors for their excellent contributions. I would also like to express my gratitude to the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Director Publication), Mr. Shehzad Naqvi (Senior Manager

ik

Publications) and Ms. Fariya Zulfiqar (Assistant Manager Publications) for their hard work and persistent efforts.

Prof. Atta-ur-Rahman, *FRS*

Kings College

University of Cambridge

Cambridge

UK

List of Contributors

Alexandra Grubman	Department of Pathology, The University of Melbourne, Victoria, Australia
Almir Fajkic	Department of Pathophysiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Almira Hadzovic-Dzuvo	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Amela Devisevic	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Amina Valjevac	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Andreia Corciova	Department of Drugs Analysis, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
Anton Glasnović	Zagreb University School of Medicine, Zagreb, Croatia
Asija Zaciragic	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Asmaa Althani	Biomedical Research Center, Qatar University, Doha, 2731, Qatar Department of Health Sciences, College of Arts and Science, Qatar University, Doha, 2731, Qatar
Bianca Ivănescu	Department of Pharmaceutical Botany, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
Calin Corciova	Department of Biomedical Sciences, Faculty of Biomedical Engineering, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
Carlo Cenciarelli	CNR-Institute of Translational Pharmacology, <i>Via Fosso del Cavaliere</i> , 100-00133 Roma, Italy
Daniela Matei	Department of Biomedical Sciences, Faculty of Biomedical Engineering, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
Hany E. Marei	Biomedical Research Center, Qatar University, Doha, 2731, Qatar
Jaana Suhonen	Neurology Department, Al-Ahli Hospital, 6401 Doha, Qatar
Jasminko Huskic	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Marijana Bosnar Puretić	University Department of Neurology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Mohamed E. El Zowalaty	Biomedical Research Center, Qatar University, Doha, 2731, Qatar
Mohammad A. Albanna	Psychiatry Department, Hamad Medical Corporation, 3050 Doha, Qatar

lv

Nermina Babic	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Nesina Avdagic	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Orhan Lepara	Department of Human Physiology, Medical Faculty University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Paul David Dash	Department of Neurology, Johns Hopkins Bayview Memory and Alzheimer Treatment Center, Johns Hopkins University, Baltimore, USA
Sandra Morović	“Aviva” Medical Centre, Zagreb, Croatia
Tengfei Wang	Department of Pharmacology, University of Tennessee Health Science Center, Memphis, USA
Thomas Caceci	Department of Biomedical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, USA
Vida Demarin	Croatian Academy of Sciences and Arts, Zagreb, Croatia
Xin Yi Choo	Department of Pathology, The University of Melbourne, Victoria, Australia
Zlatko Trkanjec	University Department of Neurology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia

CHAPTER 1

Should Physicians Screen for Dementia in the Primary Care Setting?

Paul David Dash*

Department of Neurology, Johns Hopkins Bayview Memory and Alzheimer Treatment Center, Johns Hopkins University, Baltimore, United States

Abstract: The question of possible benefits of physicians screening for dementia in elderly patients in the outpatient setting remains open. Although no controlled studies have thus far been able to conclusively demonstrate that doing so is in fact beneficial, the end points of such studies, such as mortality, are rather crude. Increasingly, there are arguments that harder to track end points need to be examined in more detail, and that earlier recognition of cognitive impairment can potentially have a significant impact on a number of clinical matters. These include, for example, recognition of potential problems with medication compliance, driving risk, predicting post-operative delirium, and allowing more time for patient and family planning of finances and living arrangements, as well as recommending life style changes in diet and exercise habits that may help retard the progression of early cognitive impairment. In this article we will discuss evidence regarding these points, and also give a brief outline of the pros and cons of some of the numerous brief cognitive screens that can be utilized for screening purposes.

Keywords: Alzheimer's, Dementia, Delirium, Prevention, Screening.

INTRODUCTION

This article addresses a central question: can screening for dementia make a meaningful difference in patient care and outcomes? There are several components to this question. What makes up a “meaningful difference” in patient

* **Corresponding author Paul David Dash:** Department of Neurology, Johns Hopkins Bayview Memory and Alzheimer Treatment Center, Johns Hopkins University, Baltimore, United States; Tel: 410-522-9940; Fax: 410-522-9954; E-mail: Pdash1@jhmi.edu

care? What makes up a “meaningful difference” in patient outcome? What patient outcomes are we talking about exactly? For example, not only longevity, but also quality of life for the patient and caregiver, and intangible outcomes such as better ability for the patient and family to plan for the future must be taken into account and may be difficult or even impossible to quantify. Another question before deciding to proceed with dementia screening is whether its benefits outweigh the risks. For example, a false positive screen can lead to costly additional testing and unnecessary anxiety. An additional question, if we decide in favor of screening for dementia, is what instruments to use as the screening tools. (We should note that we may use Alzheimer’s and dementia somewhat interchangeably in this article; Alzheimer’s disease is of course the most common cause of dementia in the elderly, and some studies take steps to try to exclude other forms of dementia).

Several reviews on this topic have been published previously. In 2003, the US Preventive Service Task Force published its review, with the conclusion that there was not enough evidence to support routine dementia screening [1]. Subsequently, a work group convened by the Alzheimer’s Foundation of America and the Alzheimer Drug Discovery Foundation in 2011, which included the lead author in the 2003 study, argued that screening could be helpful in improving dementia detection and treatment [2]. Some of the same authors including myself have also argued previously for the value of dementia screening, pointing out several of the possible advantages discussed in detail below [3].

Screening for a disease can happen at the population or individual level. Examples of population screening include national level decisions to do mass screenings of subpopulations for a disease, such as mammography for women over a certain age for breast cancer, or colonoscopies for those over 50 for colon cancer. Individual level screening, also known as case finding, occurs at the individual patient-physician level. Examples include routine blood pressure checks at every doctor visit, or somewhat more controversially, PSA screening for older men. The focus here is on identifying existing disease in those who don’t know they have it. This article is concerned only with the case finding level of screening, as the title implies.

SECTION 1: SHOULD WE SCREEN FOR DEMENTIA?

Considerations in Screening for a Disease

Before we even get to the question of screening for dementia specifically, we need to consider generally what makes a disease worth screening for, and see whether dementia fits into that category. There are several obvious and not so obvious criteria for a disease to be considered worth screening. Although detailed criteria for screening have been developed by WHO (the Wilson criteria in 1968¹, and subsequently revised in 2008²), in my opinion the following simplified considerations are among the most important:

1. The disease should be prevalent and costly enough to make screening for it worthwhile;
2. Early stages of the disease should not be obvious, such that a screening tool to uncover it is necessary;
3. The screening tool should not be overly costly in terms of expense and physician time and must be reasonably effective;
4. The potential harm in a false positive or false negative diagnosis *via* screening does not outweigh the net benefit (which includes potential benefits from a true negative diagnosis as well as the true positives). “Harm” can reflect medical costs, such as those incurred by getting other tests in pursuit of a screen testing, as well as human suffering and other intangibles;
5. Making an earlier diagnosis actually makes a difference in disease outcome compared to later diagnosis. Obviously this is the key question.

These factors can interplay with one another. For example, on the population screening level, phenylketonuria is rare, but the screening is cheap and the treatment effective, so it along with some other rare metabolic diseases are routinely checked in newborns. On the other hand, even if earlier treatment makes only a small difference, for a common disease with inexpensive screening tests it may still be worthwhile to screen. Of course, the precise econometric values for earlier intervention savings may be impossible to quantitate. As we shall see, dementia qualifies easily on the first four criteria, but arguments persist about the fifth. That makes the decision to screen worthy of further discussion.

Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders

Asija Zaciragic^{1,*}, Nesina Avdagic¹, Nermina Babic¹, Amela Devisevic¹, Amina Valjevac¹, Almir Fajkic², Jasminko Huskic¹, Almira Hadzovic-Dzuvo¹ and Orhan Lepara¹

¹ *Department of Human Physiology, Medical Faculty University of Sarajevo, Bosnia and Herzegovina*

² *Department of Pathophysiology, Medical Faculty University of Sarajevo, Bosnia and Herzegovina*

Abstract: The inability of drugs based on the amyloid-clearing strategies to provide benefits for Alzheimer's disease (AD) patients has led to widely accepted notion that the paradigm in dementia research should be broadened beyond amyloid deposition and clearance. In recent years significant overlap between cardio-metabolic risk factors and cognitive decline has been reported. Consistent with these observations, the importance of endothelial dysfunction in the development of AD has been highlighted. According to newly proposed "vascular hypothesis" for AD development, vascular risk factors lead to blood-brain barrier (BBB) dysfunction and a reduction in the cerebral blood flow. These two detrimental vascular changes result in the reduction of amyloid- β clearance as well as in its increased production leading to consequent amyloid- β accumulation. The increase in amyloid- β leads to neuronal dysfunction and injury causing cognitive dysfunction and neurodegeneration with consequent dementia. Furthermore, a growing body of evidence also suggest that the impaired structure and function of cerebral blood vessels and cells in AD patients is mediated by vascular oxidative stress as well as by chronic low-grade inflammation. The importance of inflammatory changes in many age-related diseases including dementia has led to

* **Corresponding author Asija Zaciragic:** Department of Human Physiology, Medical Faculty University of Sarajevo, Cekalusa 90, 71000 Sarajevo, Bosnia and Herzegovina; Tel: 00 387 33 203 670; Emails: zarias@lol.ba, asija.zaciragic@mf.unsa.ba

coining and use of the term “inflammaging” to indicate that ageing is accompanied by a low-grade chronic up-regulation of certain pro-inflammatory responses.

The aim of this chapter is to provide a comprehensive insight into currently available evidence on molecular pathways and players implicated in the above mechanisms. Furthermore, chapter summarizes findings from ongoing clinical trials and results from studies using novel pharmacological therapeutics targeting endothelial dysfunction and chronic low-grade inflammation as pathophysiological events that contribute to the onset and development of dementia disorders.

Keywords: Alzheimer's disease, Alzheimer's disease clinical trials, Cardio-metabolic risk factors, Chronic low-grade inflammation, Cognitive decline, Cytokine suppressive anti-inflammatory drugs, Dementia disorders treatment, Endothelial dysfunction, Endothelin receptor antagonists, Inflammaging, Nonsteroidal anti-inflammatory drugs.

INTRODUCTION

Prevalence of dementia significantly increases with age and Alzheimer’s disease (AD) accounts for up to 75% of cases. AD represents neurodegenerative disorder that affects nearly 2% of the population in industrialized countries [1]. Based on a data from 2010, AD affects 25 million people worldwide [2]. Since advanced age is the most significant risk factor for AD, medical and other kinds of costs of this disease cannot be overlooked. AD has enormous impact worldwide on the affected individuals, caregivers and overall public health care system. Individuals suffering from AD have significantly shortened life expectancy, their quality of life is drastically decreased and in many cases they require institutionalization caused by their physical disability. Studies have shown that AD patients have two-to fivefold increased risk of death and median survival time for newly diagnosed AD patients is from 3 to 6 years. Shorter survival is often reported for those AD patients that have poorer cognitive function, low education level, and comorbidities such as heart disease, hypertension and diabetes. Furthermore, white race, older age and male sex are associated with shorter life expectancy in individuals that suffer from AD [3]. Alzheimer’s Association data from 2009 have revealed that in the US the annual costs for patients with AD and other forms of dementia were estimated to be US\$148 billion plus US\$94 billion of unpaid care

service [4]. Having in mind progressive nature of AD and a fact that its adequate treatments are still lacking, this disease represents tremendous burden for family members and overall society since AD patients require permanent care and therapy. At present there are no treatments that can stop or reverse neurodegeneration typical for AD. However, better understanding of AD etiology and pathophysiology will lead to the discovery of effective preventive and therapeutic approaches that will reduce incidence and improve treatment of AD.

Pathogenesis of AD is multifactorial and yet fully unknown. Known risks factors for AD include age, genetic, environmental, vascular, life-style factors and low educational income. This disease is neuropathologically characterized by presence of neurofibrillary tangles and senile neuritic plaques, amyloid- β peptid deposits and widespread neuronal loss. Main symptoms of AD are cognitive decline, memory loss, altered behavior and language deficit. As they progress in time, these symptoms lead to severe impairment in daily functioning and in later stages AD patients require total care [5].

AD is often preceded by ‘mild cognitive impairment’ (MCI). By widely accepted definition MCI represents a transitional state between normal aging and developed dementia. It is characterized by greater cognitive decline than expected for the age of the affected individuals but with still preserved activities of daily functioning. Between 3% and 19% of adults over the age of 65 suffer from this condition, and according to current evidence more than a half of individuals with MCI will develop dementia within 5 years [6, 7]. Significant efforts are made in early diagnosis of this condition and in its proper pharmacotherapy so that development of dementia in MCI suffering patients is prevented.

As there is yet no reliable peripheral biochemical marker for the AD, definitive diagnosis of AD can only be confirmed by postmortem examination of the brain that must contain sufficient number of plaques and tangles. Extracellular deposits of fibrils and amorphous aggregates of amyloid β -peptide ($A\beta$) form plaques, and intracellular fibrillar aggregates of the microtubule-associated protein tau which exhibit hyperphosphorylation and oxidative modifications form neurofibrillary tangles. Plaques and tangles are present mainly in brain regions involved in learning, memory and emotional behaviors such as the entorhinal cortex, hippo-

CHAPTER 3

Recent Clinical Developments in Alzheimer's Disease

Xin Yi Choo* and **Alexandra Grubman**

Department of Pathology, The University of Melbourne, Victoria, Australia

Abstract: Alzheimer's disease is the most common neurodegenerative disease. Despite intensive research, promising therapies have failed to translate to the clinic. This chapter will review the prevailing mechanistic hypotheses to explain AD pathogenesis, including the cholinergic, amyloid-cascade, inflammatory and metal dyshomeostasis theories, present an update on the clinical developments in therapies targeting each of the hypotheses, and highlight promising areas requiring further research.

Keywords: Alzheimer's disease, Amyloid antibodies, Amyloid cascade hypothesis, Cholinergic hypothesis, Clinical trials, COX inhibitors, Familial, Metal homeostasis, Metal ionophores, Multi-targeting, Neuroinflammation, Secretase modulators, Sporadic.

INTRODUCTION

Alzheimer's disease (AD) is the most common neurodegenerative disease (NDD), with age being the most common risk factor [1]; it is expected to affect 1 in every 85 people worldwide by 2050 [2]. The clinical symptoms of AD include progressive cognitive and functional impairment [3]. AD is classified into two broad categories. Sporadic late onset AD (LOAD), usually occurring after the age of 65, accounts for greater than 95% of AD cases [4], while early onset AD (EOAD), which occurs before the age of 65, accounts for the remaining AD

* **Corresponding author Xin Yi Choo:** Level 6 West, Department of Pathology, Medical Building, Grattan St, The University of Melbourne, Parkville 3010, Victoria, Australia; Tel: +61 3 8344-4288; E-mail: xychoo@student.unimelb.edu.au

occurrences (<5%) [4, 5]. Early onset familial AD (EOFAD), caused by mutations in the presenillin-1 (*PSEN1*), presenillin-2 (*PSEN2*) or amyloid precursor protein (*APP*) genes accounts for 1-2% of AD cases [6, 7]. The remaining 3-4 % of AD patients The remaining 3-4 % of AD patients are expected to carry an undetermined deterministic mutation that causes the early disease onset [6]. In contrast, the presence of $\epsilon 4$ allele (ApoE4) of apolipoprotein E (*APOE*) has been recognised as a major genetic risk factor for LOAD [8]. Pathological hallmarks of AD are comprised of accumulation of extracellular amyloid-beta ($A\beta$) plaques, the presence of intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated microtubule associated protein Tau, and brain atrophy of the hippocampal and neocortical regions as a result of neuronal and synaptic loss [9]. Other established pathologies associated with AD include oxidative stress-induced damage, neuroinflammation and bio-metal dyshomeostasis (see [10 - 12] for reviews).

Although extensive research has helped to better understand the disease, the aetiology of AD has remained indistinct. This lack of knowledge greatly impedes the progress of diagnostic advancements and drug development. The gold standard for AD diagnosis is through post-mortem brain autopsy verification of disease histopathology [13]. Besides cases with detectable genetic mutations, clinical diagnosis of probable AD is carried out using criteria-based approaches [13 - 16], taking into account factors such as cognitive and behavioural performance, biological evidence and exclusion criteria. Increasingly, it is recognised that neuropathological changes can occur over long periods before patients begin to display clinical symptoms of AD [15, 17]. As such, this asymptomatic preclinical stage of disease is viewed as the golden opportunity for early therapeutic intervention. Unfortunately, with the lack of biomarker(s) that can accurately predict progression to AD and the lack of effective therapeutic options, early targeting is currently unavailable as a therapeutic approach. Interestingly, transcriptome analysis of post-mortem tissues from cognitively normal control patients, mild cognitive impairment (MCI) patients and AD patients, suggest that distinct changes in expression of genes relating to synaptic function [18 - 20], energy metabolism [18, 20] and inflammation [21, 22] occur in advance of progression to pathological stage of AD. Transcriptional changes

relating to aging and AD were also observed in young 3xTg-AD mice prior to developing AD phenotype [23]. These suggest pathways that can be explored as early targets for therapeutic intervention in AD.

Several different disease hypotheses have been generated to attempt to explain the origin of AD. Parallel with the development of the various hypotheses, proponents of individual hypotheses have also investigated therapeutic strategies targeted at the individual pathways predicted to be perturbed in AD. These strategies include targeting of the cholinergic system and other neurotransmitters, $A\beta$, NFT, neuroinflammation and bio-metal dyshomeostasis. To impede the rate of cognitive decline, early therapeutics mainly focused on targeting the central nervous system (CNS) to boost CNS functions. $A\beta$ and NFT, popularly believed to drive AD progression, also became common targets for therapeutic intervention. With strong evidence demonstrating the detrimental role of neuroinflammation in propagating AD, anti-inflammatory therapeutics became widely adopted to curb damaging inflammatory processes. In recent years, with improved understanding of bio-metal deregulation in AD, novel strategies have targeted restoration of metal homeostasis. Nonetheless, out of over 150 therapeutics clinically tested in humans to date or currently in clinical trials, only 5 have been approved for use in the treatment of AD [24]. While the drugs currently approved for AD provide some symptomatic benefit, no available drug delivers a disease modifying effect, particularly for advanced stages of disease [25].

In this review, we will discuss the proposed mechanisms, as well as success and failure of therapeutic strategies developed in line with the (a) cholinergic hypothesis, (b) amyloid cascade hypothesis, (c) inflammatory hypothesis and (d) metal hypothesis in relation to AD. For comprehensive reviews of Tau and oxidative stress biology in AD and Tau-directed and anti-oxidant therapeutic strategies, refer [26] to and [27] respectively.

Therapeutic Strategies and Clinical Trials

Cholinergic Hypothesis

Although significant progress has been made in understanding the molecular mechanisms driving AD, most currently approved therapeutic strategies are still

Recent Perspective About the Amyloid Cascade Hypothesis and Stem Cell-Based Therapy in the Treatment of Alzheimer's Disease

Hany E. Marei^{1,*}, Asmaa Althani^{1,2}, Jaana Suhonen³, Mohamed E. El Zowalaty¹, Mohammad A. Albanna⁴, Carlo Cenciarelli⁵, Tengfei Wang⁶ and Thomas Caceci⁷

¹ Biomedical Research Center, Qatar University, Doha, 2731, Qatar

² Department of Health Sciences, College of Arts and Science, Qatar University, Doha, 2731, Qatar

³ Neurology Department, Al-Ahli Hospital, 6401 Doha, Qatar

⁴ Psychiatry Department, Hamad Medical Corporation, 3050 Doha, Qatar

⁵ CNR-Institute of Translational Pharmacology, Via Fosso del Cavaliere, 100-00133 Roma-Italy

⁶ Department of Pharmacology, University of Tennessee Health Science Center, Memphis, Tennessee, USA

⁷ Department of Biomedical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA

Abstract: Alzheimer's disease (AD) is a complex neurodegenerative condition that is clinically characterized by impaired cognitive functions. The major morphologically observed lesion of AD encompasses the accumulation of extracellular amyloid aggregates (plaques) formed of amyloid- β (A β) protein and of intracellular neurofibrillary tangles (NFT) of hyperphosphorylated Tau protein. According to the currently accepted amyloid cascade hypothesis, the major induction factor underlying the loss of cholinergic neurons in the cortex and hippocampus is the pathological accumulation of a smaller protein fragments known as amyloid- β which in turn is derived from a larger membrane protein called amyloid precursor protein (APP). Based

* **Corresponding author: Hany Marei:** Biomedical Research Center, Qatar University, P.B. Box 2713, Doha, Qatar; Tel: (+ 974) 4403-6817; E-mail: hmady@qu.edu.qa

on this hypothesis, several diagnostic and drug-based therapeutic interventions were suggested, mostly targeting amyloid- β and hyperphosphorylated Tau proteins. Several data have emerged that might indicate the inconsistency of the amyloid cascade hypothesis. Moreover, due to the purely palliative nature of AD drugs used so far, new stem cell-based therapy has been suggested as a promising potential therapeutic approach. Several cell sources have been used, such as embryonic stem cells, neural stem cells, mesenchymal stem cells, and induced pluripotent stem cells. While this suite of cell-based trials has shown promising results in preclinical paradigms, stumbling blocks still exist in the current treatment regimens. The present review highlights the recent perspective that argues against the long standing amyloid cascade hypothesis as well as the major efforts in the experimental application of stem cell-based therapies used as treatment options for AD, and discusses the major impediments against their successful translation into clinical.

Keywords: A β 42 peptides, Alzheimer's disease, Amyloidogenesis, Amyloid precursor protein (APP), Neuronal stem cells, Pathogenesis, Senile, plaques, Stem cells-Therapy.

ALZHEIMER'S DISEASE PATHOPHYSIOLOGY

Since the discovery of Alzheimer's disease (AD) in 1907, two major pathological AD associated proteins composed of amyloid β (A β), a small fragment of a larger precursor protein called amyloid precursor protein (APP) and a microtubule-associated intraneuronal tau protein have been incriminated as the major etiology underlying the massive loss of cholinergic neurons in the cortex and hippocampus of the brain [1 - 3]. Using Sephadex G-100 column chromatography, and by high performance liquid chromatography, a purified protein was derived from fibrils in cerebrovascular amyloidosis associated with Alzheimer's disease has been isolated. This protein have no homology with any protein sequenced, and may provide a diagnostic test for Alzheimer's disease and a means to understand its pathogenesis [4].

A monoclonal antibody to the microtubule-associated protein tau (tau) labeled some neurofibrillary tangles and plaque neurites, the two major locations of paired-helical filaments (PHF), in Alzheimer disease brain. [5].

Massive neuronal loss is associated with major synaptic losses reflected clinically

as gradual loss of recent memory functions and late-life dementia [6]. Based on the observed AD-associated pathology, the “amyloid cascade hypothesis,” was proposed [7, 8]. Major evidence for this hypothesis included the discovery that mutations of APP genes are among the major genetic makeup of AD [9, 10].

During the last century, the amyloid cascade hypothesis represented the roadmap by which AD can be diagnosed and treated. Unfortunately, in most cases, this simple straightforward linear hypothesis failed to explain the complex biological and molecular pathways associated with the perplexing and devastating AD pathology. Smith *et al.* [11] stated that alternate interpretations of old data as well as new evidence indicates that amyloid-beta, far from being the harbinger of disease, actually occurs secondary to more fundamental pathological changes and may even play a protective role in the diseased brain. These findings bring into doubt the validity of the Amyloid Cascade Hypothesis as the central cause of Alzheimer disease and, consequently, the potential usefulness of therapeutic targets against amyloid-beta protein. This became more clear when many of A β and tau-protein-based preclinical and clinical trials failed to restore lost neuronal and cognitive functions associated with AD pathology [12, 13].

The palliative nature of AD drugs developed so far and the failure of amyloid and tau-based therapeutic protocols have prompted several investigators not only to point out the possible inconsistency of the amyloid cascade hypothesis, but also to start searching for novel non-drug based therapeutic protocols such as stem cell-based therapy [14]. In this respect, several cell sources have been used with the aim to provide an ample supply of suitable progenitor cells that might restore the lost neuronal and synaptic elements associated with AD [15, 16].

This review explores novel data that may modify or replace the amyloid cascade hypothesis, and presents major experimental findings relevant to stem cell-based therapy for AD.

GENERAL VIEW ABOUT AD

AD represents one of the major public health burdens in elderly population. The ratio of AD occurrence is approximately one to nine in individuals of age < 65 year old and such figures worsen as the population of the world ages to approximately

CHAPTER 5

Current Concepts in Management of Alzheimer's Disease

Vida Demarin^{1,*}, Zlatko Trkanjec², Marijana Bosnar Puretić², Sandra Morović³ and Anton Glasnović⁴

¹ *Croatian Academy of Sciences and Arts, Zagreb, Croatia*

² *University Department of Neurology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia*

³ *“Aviva” Medical Centre, Zagreb, Croatia*

⁴ *Zagreb University School of Medicine, Zagreb, Croatia*

Abstract: Alzheimer's disease (AD) is a neurodegenerative disease characterized by amyloid plaque and neurofibrillary tangles formation in the brain tissue. It is a progressive disease with death as the final outcome. In 2012 there were 35.6 million affected people worldwide and this number is constantly increasing. The main risk factor is age and life expectancy after the diagnosis is approximately ten years. The most important diagnostic procedures are neurocognitive tests, which are used to assess behavior and thinking abilities, while neuroimaging is used to exclude other brain pathologies and confirm the specific atrophic changes. Although a large number of studies have investigated this issue, no effective treatment for AD has been found. Most frequently used medications are ACh esterase inhibitors, mainly donepezil, rivastigmin and galantamine, and N-methyl-D-aspartate (NMDA) receptor antagonist, memantine, but they are mostly used to relieve the symptoms. Therefore, the emphasis should be put on early disease detection and delaying cognitive impairment through lifestyle modifications, such as increased physical activity, healthy nutrition, and mental training. The disease influences not only the patients' quality of life, but also that of the caregivers, and represents a heavy financial burden for the society as a whole.

* **Corresponding author Vida Demarin:** Croatian Academy of Sciences and Arts HR-10000, Zagreb, Trg Nikole Šubića Zrinskog 11 Croatia, Tel: +38514895111; Fax: +38514819979; Emails: vida.demarin@gmail.com, vida.demarin@zg.t-com.hr

Atta-ur-Rahman (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

Keywords: ACh esterase inhibitors, Allopregnanolone, Alzheimer's disease, Amyloid, Bapineuzumab, Biomarkers, Cannabinoids, Caregiver, Costs, Dementia, Diet, Dimebon, Herpes simplex virus, Immunotherapy, Insulin, Mild cognitive impairment, NMDA antagonists, PET, Statins, Tau protein.

INTRODUCTION

Alzheimer's disease (AD) is the most common form of neurocognitive impairment. It usually affects patients older than 65 years [1, 2], and when it is diagnosed in younger age groups it is referred to as early-onset AD. In 2012, there were 35.6 million affected people worldwide, and by 2050 this number is expected to increase to 1 in 85 people [3]. The disease was first described in 1906 by German physician Alois Alzheimer [1, 4]. He described the case of his patient Auguste D. who at the age of 40 experienced behavioral and memory changes, such as comprehension and memory impairment, dyslexia, dysgraphia, dysphasia, spatial disorientation, unpredictable behavior, paranoia and auditory hallucinations, psychosocial impairment, as well as insomnia. After her death at the age of 55, pathoanatomical examination showed a significantly reduced cerebral cortex with visible “miliary foci” (what is today called amyloid or senile plaques) and clumps and condensations of intracellular fibrils, which Alzheimer called “neurofibrillary degeneration” and are today known as neurofibrillary tangles [5].

EPIDEMIOLOGY

The incidence of AD is 5-8/1000, while that of all dementias is 10-15/1000. The most important risk factor for the development of AD is age – the risk doubles every five years after the age of 65 [7 - 9]. Women are at greater risk than men, especially after the age of 85 [10].

The prevalence of AD has doubled since the beginning of the 20th century, probably due an increase in life expectancy [6]. When analyzing the disease prevalence in particular countries we should take into consideration the mean age of the population, because less developed countries have shorter life expectancy [11 - 13].

SYMPTOMS AND DISEASE COURSE

AD develops slowly but progressively and the final outcome is death. Its progression is divided into four stages: preclinical, early, moderate, and advanced stage, with each stage being marked by further increase in cognitive and functional impairment [3, 14]. Diagnosis is usually established when symptoms start to affect patients' activities of daily life, while a few years before that, patients may experience mild cognitive impairment (MCI) [15]. MCI affects executive functions, such as attentiveness and abstract thinking, depression, apathy, irritability and reduced awareness of memory impairment [16 - 20]. There is still a dispute whether it corresponds to a different diagnostic category or it is in fact a preclinical stage of AD [21 - 22]. Early interventions can lead to significant delay in disease onset and symptom improvement, which is why emphasis should be put on disease prevention.

Early Stage

The first symptoms that lead to AD diagnosis are memory and learning impairment, while some patients develop more evident problems, such as language and executive functions impairment, and impairment of perception (agnosia) and movement execution (apraxia). Not all aspects of memory are equally impaired: episodic memory is less impaired than semantic memory, so major problems are reduced vocabulary and word fluency, both orally and in writing [16 - 18]. At this stage, the patient appropriately communicates basic ideas [18, 23], but frequently faces problems with fine motor tasks such as writing, drawing, dressing and planning of certain movements, Early symptoms often remain unnoticed or are misinterpreted as being related to the normal aging process.

Moderate Stage

With further disease progression, patients gradually lose their independence and become unable to perform most of the daily activities [16]. They experience reading, writing, and speech impairments, particularly in the form of paraphasias, *i.e.*, incorrect word substitutions [18, 23]. Also, impairments arise in the domain of complex motor actions and long-term memory [24]. Patients have a tendency to

Natural Compounds from Plants Targeting Alzheimer's Disease

Andreia Corciova¹, Daniela Matei^{2,*}, Calin Corciova² and Bianca Ivănescu³

¹ *Department of Drugs Analysis, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania*

² *Department of Biomedical Sciences, Faculty of Biomedical Engineering, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania*

³ *Department of Pharmaceutical Botany, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania*

Abstract: Alzheimer's disease is a common form of dementia. Drugs currently available for treatment of Alzheimer's disease are only symptomatic and act by augmenting the level of acetylcholine. These drugs do not stop or delay the evolution of disease and manifest specific adverse effects that limit their use. In this context, it is crucial the development of new drugs that will target the causal agent of disease. Such compounds that intervene at different levels in the pathogenesis of Alzheimer's disease were identified in plant extracts.

In this chapter, we propose an overview of some compounds that have anti-amyloidogenic activity of which the most important are: curcuminoids, ellagic acid, gallic acid, salvianolic acid B, resveratrol and epigallocatechin-3-gallate. Besides the mechanism and biological actions, this chapter will present the vegetal products from which the active compounds are extracted, methods of extraction, identification and quantification. Selected techniques will be compared in terms of optimal conditions for extraction. Moreover, methods for identification and quantification will be described in terms of analytical conditions. Nature remains an important resource of active molecules and a hope in treating Alzheimer's disease.

* **Corresponding author Daniela Matei:** Department of Biomedical Sciences, Faculty of Medical Bioengineering, "Grigore.T.Popa" University of Medicine and Pharmacy. 9-13 Kogalniceanu Street, 700454, Iasi, Romania; Tel/Fax: +40 232 213573; Cell: +40 728 024243; E-mails: dvm2202@yahoo.com, daniela.matei@umfiasi.ro.

Keywords: Alzheimer's disease, Methods of extraction, Oxidative stress, Solvents, Vegetal products.

INTRODUCTION

Alzheimer's disease, named after the neurologist Alois Alzheimer (1864-1915) is a type of dementia characterized by a deterioration of mental capacity, which installs with age. Increasing life expectancy increases the risk of this disease.

Worldwide there are currently 24.3 million people with dementia and 4.6 million new cases are diagnosed annually. It is estimated that the number of people with dementia doubles every 20 years and for 2050 it is forecast to be 115 million people suffering from AD [1].

Hallmark brain abnormalities in AD are the formation of the senile plaques and neurofibrillary degeneration, processes that gradually causes the death of neurons, especially in the brain structures involved in cognitive processes such as frontal cortex, hippocampus, basal nucleus of Meynert [2].

Drugs currently available for treatment of Alzheimer's disease are only symptomatic and act by augmenting the level of acetylcholine, compensating for loss of cholinergic function: acetylcholine precursors, muscarinic agonist, nicotinic agonists and choline esterase inhibitors [2].

These drugs do not stop or delay the evolution of disease and manifest specific adverse effects that limit their use. In this context, the development of new drugs that will target the causal agent of disease is crucial.

Such compounds that intervene at different levels in the pathogenesis of Alzheimer's disease were identified in plant extracts.

In this chapter we propose an overview of the curcuminoids, ellagic acid, gallic acid, galagic acid salvianolic acid B, rosmarinic acid, punicalagin, resveratrol, epigallocatechin-3-gallate, oleanolic acid, oleuropein, ginkgolide and biblobalide. These compounds act through diverse mechanisms in blocking the amyloid cascade: by stopping the aggregation of amyloid beta peptide and fibril formation, promoting the disaggregation of formed fibrils, inhibiting beta-

secretase and gamma-secretase or increasing alpha-secretase activity, thus increasing the production of non-amyloidogenic peptide.

Knowing that beta-amyloid peptide damages neurons by generating reactive oxygen species in the process of self-aggregation, the antioxidant activity of plant compounds must be taken into account as well. The majority of tests highlighting anti-amyloidogenic activities of natural compounds were performed *in vitro*, so further research is needed for confirmation of these activities *in vivo* and clinical trials for introduction of new drugs in therapy.

Besides the mechanism and biological actions, this chapter will present the vegetal products from which the active compounds are extracted, methods of extraction, identification and quantification. Selected techniques will be compared in terms of optimal conditions for extraction, such as solvents, modifiers used to improve the extraction, temperature, pressure and extraction time. Moreover, methods for identification and quantification will be described in terms of analytical conditions: derivatization of compounds, stationary and mobile phase, temperature, detector type, analysis time, limit of detection, limit of quantitation, correlation between the method/extraction solvent and the recovered concentration.

Knowing the different types of analysis methods that can be used for the extraction, separation, identification and quantification of proposed compounds is of great importance, the analysts can choose the most suitable and effective technical conditions, taking into account the available equipment.

Considering the fact that natural compounds have fewer side effects, are well tolerated and can be further used as models for the synthesis of novel drugs, nature remains an important resource of active molecules and a hope in treating Alzheimer's disease.

PATHOPHYSIOLOGICAL MECHANISMS

Beta-Amyloid and Tau Proteins

The best known pathophysiological mechanisms involved in AD are increased

SUBJECT INDEX

A

- Aβ42 peptides 146, 218
- Aβ 55, 62, 66, 87, 89, 90, 94, 95, 104, 151, 153, 182, 183, 192, 221, 225, 230, 236, 240, 243
- aggregation 90, 95, 104, 230, 243
- peptides 55, 62, 87, 89, 94, 104, 153, 183, 192, 221, 225, 230, 240
- production 66, 151, 182, 236
- Accelerated solvent extraction 258, 261, 262
- Acetylcholine 44, 86, 215, 216, 218, 223, 227
- ACh 86, 87
- AChEIs 86, 87, 88
- ACh esterase inhibitors 176, 177, 188, 195
- Acid 215, 216, 234, 242, 243, 244, 245, 247, 249, 250, 251, 252, 253, 254, 256, 257, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 274, 275, 277
- acetic 264, 266, 267, 270, 271, 275
- caffeic 242, 244, 249, 250, 254
- ellagic 215, 216, 234, 251, 253, 254, 265, 267, 277
- formic 266, 267, 269, 270, 272
- gallagic 253, 254
- gallic 215, 216, 234, 242, 251, 252, 253, 257, 265, 268
- ginkgolic 247
- oleanolic 216, 243, 249, 256, 257, 263, 275
- phenolic 252, 265, 266
- phosphoric 269, 274, 275
- polyphenolic 244, 245
- β-punicalagin ellagic 266, 267
- rosmarinic 216, 244, 249, 250, 252, 253, 254, 265, 266, 268, 269, 277
- salvianolic 215, 244, 245, 250, 252, 253, 268, 277
- trifluoroacetic 269, 272
- water/methanol/acetonitril/phosphoric 268
- Activities 86, 106, 107, 245
- anti-inflammatory 245
- cholinergic 86
- ionophore 106, 107
- Addenbrooke's cognitive examination (ACE) 31, 32
- AD-related neuroprotective effects 87
- Aducanumab 91, 94
- Advanced aging 54
- Air pollution 182
- Allopregnanolone 177, 193
- Alzheimer disease cooperative study 18
- Alzheimer disease neuroimaging initiative (ADNI) 23
- Alzheimer's disease 6, 14, 15, 146, 177, 215, 217
- amyloid 146, 177
- early 6
- mild 14, 15
- moderate 15
- treating 215, 217

- Alzheimer's disease
 anti-inflammatory prevention trial 64
- Alzheimer's disease
 pathophysiology 146
- Amnestic MCI 23, 27, 193, 194
- Ampelopsin 230, 231
- Amyloid 16, 41, 48, 56, 58, 83, 85, 89, 90, 108, 145, 146, 147, 149, 151, 152, 153, 154, 161, 192, 224, 243, 245
 aggregation 108, 192, 243
 antibodies 83, 154
 cascade hypothesis 83, 85, 89, 90, 145, 146, 147, 149, 151, 152, 153, 154, 161
 deposition 16, 41, 48, 56, 58, 224
 fibrils, preformed 245
- Amyloidogenesis 146
- Amyloidogenic 55, 89, 91
- Amyloid plaques 55, 66, 151, 158, 176, 179, 181, 192, 218
- Amyloid precursor protein (APP) 44, 55, 84, 89, 91, 96, 100, 145, 146, 149, 151, 152, 153, 179, 180, 183, 218, 234
- Angiogenesis 19, 224
- Anosognosia 6, 15, 22, 23
- Anti- $\alpha\beta$ antibodies 90, 91, 94
- Anti-inflammatory drugs 42, 63, 64, 65, 100, 103, 153, 186
- 1-antichymotrypsin 58
- Antigen presenting cells (APCs) 90, 112
- Antioxidant 54, 65, 194, 235, 251, 252
- Apigenin 65, 66, 249
- ApoE 84, 88, 93, 110, 111, 112, 153, 180, 192
- Apolipoprotein 84, 153, 180
- APP genes 96, 180
- APP processing 95, 96, 97
- α -punicalagin 266, 267
- α -secretase activity 91, 96, 236, 239
- Assam tea 238
- Astrocytes 58, 99, 148, 155, 156, 157, 158, 160, 162, 221, 222, 225
- Atherosclerosis 47, 48, 53, 57, 244
- Atsm 107
- Australian imaging, biomarkers and lifestyle (AIBL) 111
- B**
- Bapineuzumab 91, 92, 93, 111, 177, 192
- BBB permeability 51
- Begacestat 91, 98
- β -secretase 234
- Bilobalides 247, 256, 257, 264, 276, 277
- Bioactive compounds 239, 242, 245, 264, 265, 278
- Bio-metal dyshomeostasis 84, 85
- Bis-demethoxycurcumin 254, 255, 262, 271
- Blood brain barrier (BBB) 41, 45, 50, 51, 66, 107, 112, 224, 225, 229, 230, 237, 239, 245
- β -punicalagin 267

- Brain 43, 47, 49, 50, 59, 60, 84, 104, 105, 156, 161, 176, 179, 182, 183, 184, 185, 188, 216, 220, 221, 223, 224, 225
atrophy 47, 84
cells 184, 225
-derived neurotrophic factor (BDNF) 156, 220
diseases 184
glial cells 221
inflammation 49, 50, 59, 224
neurons 223
pathologies 176, 188
regions 43, 161, 183
structures 60, 216
tissues 104, 105, 176, 179, 182, 184, 185
 β -secretase 89, 91, 96, 97, 151, 240, 251
- C**
- Camellia irrawadiensis 254, 257, 260, 268
Camellia sinensis 237, 238, 251, 277
Cannabinoids 177, 193
Capillary electrophoresis 264, 273, 278
Carbon atoms 257
Cardiac diseases 244
Cardio-metabolic risk factors 41, 42, 68
Catechin quantification 274, 275
Catechins 229, 233, 239, 240, 251, 252, 263, 274, 275, 277
Catechins extraction 262
Celecoxib 64, 100, 101
Cell-based therapy 146, 147, 156, 157, 159, 160
Cells 41, 45, 51, 55, 56, 60, 90, 102, 109, 110, , 111, 155, 156, 159, 160, 161, 182, 220, 221, 222, 224, 237, 250
glial 155, 182, 220, 221
neural 159, 160, 227
patient-derived iPS 111
patient-derived neuronal 110
Cell types 59, 99, 162
Central nervous system (CNS) 49, 50, 52, 65, 85, 94, 99, 100, 101, 112, 188, 218, 220, 222, 226
Cerebral blood flow 19, 41, 45, 50, 51, 62, 223, 225
Cerebral blood vessels 41, 45, 47, 51, 55, 62
Cerebral hypoperfusion 46, 54, 55, 62, 67
Cerebral microvascular 45, 66, 67
Chemical structures 231, 253, 255, 256
Chemokines 58, 59, 221
Chinese medicine for cardiac diseases 244
Chloroform 262, 266, 271, 272
Cholinergic hypothesis 83, 85, 86, 88, 180, 218
Cholinergic neurons 86, 146, 148, 157, 159, 160, 162, 218
massive loss of 146, 148
Ciliary neurotrophic factor 157, 158
Clock draw test (CDT) 26, 27, 32

- Cochrane review 19, 25, 27
- Cognitive 3, 6, 10, 11, 12, 15, 16, 17, 18, 19, 20, 22, 23, 25, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 62, 64, 67, 68, 85, 86, 90, 94, 96, 98, 99, 102, 105, 106, 110, 113, 153, 185, 187, 188, 189, 190, 191, 193, 195, 218, 220, 222, 224, 225, 226, 227, 243, 245, 248, 249
- decline 12, 19, 22, 23, 41, 42, 43, 44, 46, 47, 48, 49, 51, 53, 54, 55, 56, 57, 58, 59, 64, 67, 68, 85, 90, 102, 105, 106, 108, 110, 147, 182, 187, 188, 191, 193, 164, 195, 224, 226, 248, 252
- deficits 86, 94, 96, 98, 153, 189, 226, 245
- dysfunction 41, 45, 46, 47, 48, 57, 62
- function 42, 54, 59, 67, 106, 108, 147, 182, 189, 194, 248, 252
- impairment 3, 6, 11, 12, 16, 17, 20, 45, 50, 113, 185, 190, 193, 218, 220, 222
- impairment/dementia 18
- performance 99, 222, 225, 227, 243, 248, 249
- retraining 189
- tests 10, 15, 23, 25
- training 19
- Combination therapies 88, 108, 109
- Co-morbidities 56, 57
- Compounds 215, 217, 244, 249, 252, 277, 278
- active 215, 217, 252, 277, 278
- polyphenolic 244, 249
- Corticotrophin-releasing factor (CRF) 219
- COX-1 64, 65, 101
- COX-2 63, 65, 101, 221, 236
- COX-independent mechanism 65
- COX inhibitors 83
- C-reactive protein (CRP) 57, 58
- Cryptotanshinone 244
- CSF A β 97
- C-terminal fragment (CTF) 91, 151
- Curcuma longa* 234, 235, 251, 271, 277
- Curcuma* species 235
- Curcumin 65, 66, 102, 109, 111, 187, 236, 237, 251, 254, 255, 262, 271, 272
- effects of 111, 236, 237
- Curcuminoids 215, 216, 235, 236, 252, 254, 255, 270, 271, 272, 273, 274, 277
- analysis 271, 273, 274
- determination 270, 272
- extraction 262
- Cytokines 42, 65, 66, 148, 182, 184, 220, 221
- Cytokine suppressive anti-inflammatory drugs (CSAIDs) 42, 65, 66
- D**
- Damage 184, 219, 220
- tissue 184
- proteins 219, 220

- Deferoxamine 105
- Delirium 3, 12, 13, 16, 17, 185
 - postoperative 12, 13
- Demented population 26
- Dementia 6, 7, 11, 15, 24, 26, 27, 41, 43, 44, 45, 50, 57, 60, 62, 64, 97, 110, 147, 182, 185, 149, 194, 248
 - complete 149
 - consequent 41, 45
 - degenerative 60
 - detecting 27
 - developed 43, 50
 - developing 7, 57
 - diagnosed 194
 - early 6
 - late-life 147
 - mild 26
 - mild-to-moderate Alzheimer 248
 - mild-to-severe 248
 - mimicking 185
 - mixed 182
 - moderate 24, 97
 - multi-infarct 248
 - onset of 44, 62, 64
 - reversible 11, 15
 - stage 110
- Dementia disorders 42, 46, 61
 - development of 61
 - onset and development of 42, 46
- Dementia disorders treatment 42
- Dementia prevention 59
- Dementia progression 48, 58
- Dementia research 41, 56
- Dementia screening 4, 10, 17, 20
 - support routine 4
- Dementia screening tests 12, 16, 17, 21, 27, 29, 32
- Dementia severity 189
- Dementia syndrome 186
- Demethoxycurcumin 236, 254, 255, 262, 271
- Demetoxycurcumine 272
- Depositions, A β 87, 89, 224
- Detection
 - early disease 176, 184
 - improving dementia 4
- Detection limits 217, 272, 274, 275
- Deterioration, disease-related 105
- Determination, densitometric 271, 272
- Diabetes mellitus (DM) 47, 48, 182, 223
- Diagnosis, earlier dementia 11
- Dichlormethane 266, 271
- Diethyl ether 265, 266
- Dimebon 177
- Disease
 - age-related 41, 45, 55, 56
 - cardio-metabolic 53
 - cardiovascular 46, 47, 187, 195, 250
 - cardio-vascular 244
 - cerebrovascular 223
 - chronic peripheral 57
 - co-morbid 186, 191
 - concomitant 179
 - concurrent 185
 - dental 190
 - genetic 149
 - heart 42
 - human 110

- moderate 188
 - neurologic 59
 - neurological 157, 188
 - progressive 176, 190
 - propagating 99
 - vascular 48, 53, 223
 - Disease cascade 181
 - Disease histopathology 84
 - Disease hypotheses 85
 - Disease indicator, early 99
 - Disease management 186, 190
 - Disease mechanisms 109, 183
 - Disease-modifying therapies 67
 - effective 109
 - Disease onset 178
 - Disease outcomes 5, 100
 - Disease pathogenesis 108
 - Disease pathology 100, 109, 110, 192
 - multiple 107
 - Disease prevalence 21, 177
 - Disease prevention 178, 195
 - Disease process 108, 111, 155, 161
 - Disease progression 18, 68, 88, 108, 178, 193, 195
 - slow 16
 - Disease risk 187
 - Disease stages 108, 110
 - earliest 185
 - initial 188
 - Disorders, metabolic 48, 50
 - DNA oxidation 182
 - Donepezil 10, 18, 63, 86, 87, 88, 108, 176, 188, 194, 195
 - Drive disease pathologies 105
 - Dysfunction 41, 45, 49, 50, 51, 52, 53, 54, 55, 62, 111, 219, 225, 226, 228
 - cerebrovascular 52, 53, 55, 62
 - mitochondrial 54, 219, 226, 228
 - neuronal 41, 45, 49, 50
- E**
- Earlier intervention in dementia make 18
 - Early detection 11, 12, 13, 14, 111
 - Early disease onset 84
 - Early onset familial AD (EOFAD) 84, 90, 97, 110
 - Effects 88, 227, 233, 234, 102, 240, 249
 - inhibitory 102, 240
 - neuroprotective 88, 227, 233, 234, 249
 - Elective surgery 12, 13
 - Electrolyte 273, 274
 - Elements, trace 103
 - Ellagitannins 233, 253, 254
 - Embryonic stem cells (ESCs) 113, 146, 158, 159
 - Encenicline 87, 88
 - Endothelial cells 50, 51, 61, 66, 222, 223, 224
 - Endothelial dysfunction 41, 42, 45, 46, 47, 48, 49, 52, 53, 55, 61, 62, 63, 67, 219, 222, 223, 227, 228
 - Endothelial dysfunction and dementia 50

Endothelin receptor antagonists 42, 61, 62, 63
Endothelium 222, 223, 224, 227
EOAD early onset Alzheimer's disease 113
EOFAD early onset familial Alzheimer's disease 112
Epigallocatechin-3-gallate 215, 216
Epicatechin 229, 239, 274
Epicatechin gallate 239, 274
E-piceatannol 231
Epigallocatechin 239, 257, 274
Epigallocatechin gallate 239, 251, 274, 275, 277
Epigallocatechin 256, 257
ET-1, release of 62
Etanercept 66, 102
ETA receptors 61, 62
ETB receptor 61, 63
E-vitisin 231
Excitotoxicity 89, 188
Expression, altered vascular 52
Extraction 215, 216, 217, 241, 258, 259, 261, 263, 264, 265, 267, 268, 277, 278
 fluidized bed 258, 261, 278
 methods of 215, 216, 217, 241, 258, 259, 263, 264, 277
 solid phase 258, 259, 265, 267, 278
 stilbenes 261
 supercritical fluid 264
 ultrahigh pressure 263
 ultrasonic 261, 264, 267, 268
Extraction time 217, 259, 277

F

Factors 44, 45, 46, 67, 156, 157
 brain-derived neurotrophic 156
 neurotrophic 156, 157
 vascular 44, 45, 46, 67
FDA-approved drugs 86, 88
Flavonoids 241, 247, 249
Flurizan 91, 98
Forebrains 86, 160

G

Galantamine 18, 86, 87, 176, 188, 195
Galatamine 87
Gamunex 94
Gantenerumab 91, 93, 94
Genome-wide association studies (GWAS) 153, 154, 180
Ginkgo 187, 246, 247, 248, 252, 258, 277
 biloba 187, 246, 247, 252, 258, 277
 extracts 248
 leaf 247, 248
Ginkgolides 216, 247, 256, 257, 264, 276, 277
Glutamate 44, 88, 188, 219, 221
Glutathione 220
Green fluorescent protein (GFP) 157
8-secretase 89, 91, 96, 97, 98, 108, 149, 221

H

Herpes simplex virus (HSV) 177, 181, 192

Heterogenic disease profile 54

Hippocampus 51, 145, 146, 155, 156, 157, 182, 216, 218, 219, 220, 221, 222, 226, 229

HNGF 157, 158

Hopkins verbal learning test (HVLT) 29, 32

HPLC-fluorescence 276

Huntington's disease 243

Huperzine 87, 189

Hydro-alcoholic solutions 259, 260

Hydroxytyrosol 242, 243, 251

Hypertension 42, 44, 47, 61, 182, 186, 219, 223

Hypothalamic-pituitary-adrenal axis 219

I

Ibuprofen 65, 100, 101

IGFs 226, 227

IL-1 β 48, 49, 50, 58, 221, 224, 227, 236, 245

IL-6 48, 49, 50, 57, 58, 101, 220, 221, 223, 224, 227, 236

IL-8 223, 224

Immune response 52, 61, 95, 153, 192

Immunotherapies 61, 90, 95, 177, 192, 195

Indomethacin 65, 100, 101

Inflammation 57, 58, 60, 63, 64, 66, 68, 84, 98, 99, 100, 102, 109, 154, 184, 186, 218, 220, 222, 223, 228, 243

Inflammatory 46, 48, 49, 56, 57, 59, 67, 85, 89, 101, 102, 108, 184, 221, 222, 223, 227

mediators 49, 56, 57, 102, 108, 221, 224

processes 46, 48, 49, 67, 85, 184, 221, 222

responses 59, 89, 101, 221, 223, 227

Inflammatory stimulus, initial 58, 59

Infliximab 66

Inhibition of 251, 252

A β formation 251, 252

A β -induced neuroinflammation 251, 252

A β -induced neurotoxicity 251, 252

A β protein aggregation 251, 252

Inhibitors, acetylcholinesterase 251, 277

Insulin 47, 49, 158, 177, 193, 196, 219, 225, 226, 227, 228

binding of 225, 227

deficiency 226, 227

receptor binding 226, 227

receptors 225, 226

resistance 47, 49, 193, 219, 226, 227, 228

-resistant brain state 226

Interventions, anti-inflammatory 101

IPSCs 158, 159, 160

K

Kaempferol 247, 249

L

Lamiaceae family 248

Lemon balm 248, 249, 265, 266

Lewy body dementias 60, 61

Lexical fluency Tasks 27, 28

Life expectancy 42, 176, 177, 190, 195

LOAD 83, 84, 90, 100, 102, 110, 111

LOAD late onset Alzheimer's disease 113

LOAD pathogenesis 100

Locus ceruleus 218, 219

Locus coeruleus 148, 182, 183

LOD 276, 277

Long term potentiation (LTP) 90, 220

LR ratios 22

M

MAbs 91, 92, 93

humanised 93

murine 92, 93

targeting 91

Maceration 258, 260, 261, 262, 277

MACHR 86, 87

Macrophage inflammatory protein (MIP) 101, 113

Magnetic resonance imaging (MRI) 183, 194

Maidenhair trees 246

Markers, disease tracking 28

Matrix metalloproteinases 223, 224

Mayo Foundation 151, 152, 162

Medial ganglionic eminence (MGE) 158

Mediators, pro-inflammatory 49, 58, 99, 101, 102

Medication compliance 3, 11

Mediterranean 19, 187, 228, 240, 241

area 240, 241

basin 228, 240, 241

diet 19, 187

region 232, 241

Melissa officinalis 248, 249, 252, 266, 269, 277

Melissa officinalis extract 249, 250

Memory 6, 15, 23, 27, 47, 86, 96, 147, 158, 177, 178, 185, 193, 194, 218

deficits 96, 158, 185, 218

functions 23, 47, 147, 158, 193

impairment 86, 177, 178, 194

problems 6, 15, 23

tests 23, 27

Mesenchymal stem cells (MSCs) 146, 159

Metabolic diseases 5, 185, 226

rare 5

Metabolic 48, 225

substrate 225

syndrome 48

- Metal 83, 85, 103, 104, 105, 106, 107
-delivering compounds 107
dyshomeostasis 103, 104, 105, 107
homeostasis 83, 85
ionophores 83, 106
-targeting drugs 105
- Micelles 273, 274
- Microglia 51, 58, 59, 89, 93, 99, 100, 101, 102, 103, 108, 109, 110, 148, 221, 222
activated 49, 51, 58, 59, 60, 103, 221
activation of 49, 59, 60, 221, 237
- Microtubules 181, 183, 218
- Mild cognitive impairment (MCI) 9, 16, 18, 20, 23, 24, 26, 28, 29, 32, 43, 46, 50, 67, 84, 94, 97, 103, 111, 177, 178, 188, 193, 194, 220
- Miltiorrhiza 244
- Mini-cog 27, 32
- MiRNAs 184
- MMSE scores 17, 30, 32, 184
- Mobile phase methanol 276
- MoCA scores 26
- Mode, negative ionization 275, 276
- Molecules 50, 102, 182, 184, 234, 253, 255
neurotoxic 51
- Monocytes 51
- Montreal cognitive assessment (MoCA) 7, 8, 25, 26, 28, 32
- Morbidity 56
- Mortality 3, 10, 12, 56
- Mutations 84, 96, 97, 110, 149, 151, 153, 161, 179, 180
- N**
- NACHRs 86, 87
- Naproxen 64, 101
- National ambient air quality standards (NAAQSs) 182
- NDD neurodegenerative disease 113
- Negative predictive value (NPV) 21
- Nerve growth factor (NGF) 156, 157, 158
- Neural stem cells (NSCs) 89, 146, 155, 156, 157, 158, 159, 160, 161, 237
- Neurodegeneration 41, 46, 51, 54, 57, 58, 59, 60, 67, 104, 151, 192, 227, 237
progressive 54, 192
- Neurodegenerative changes 53, 55
- Neurodegenerative diseases 53, 54, 60, 83, 104, 176, 230, 237, 277
common 83
developing 277
- Neurofibrillary tangles 43, 54, 146, 148, 151, 152, 177, 182, 183, 220, 222
- Neurofibrillary tangles formation 176, 179
- Neuroinflammation 50, 58, 59, 60, 61, 62, 67, 83, 84, 85, 99, 100, 101, 103, 154, 161, 193, 195, 221, 222, 227, 239, 251, 252
chronic 60, 65

Neuronal stem cells 146
Neuronal survival 157, 225, 226
Neurons 44, 50, 65, 99, 111, 148,
155, 156, 157, 158, 159, 160,
162, 181, 182, 183, 184, 218,
219, 221, 224, 225, 228, 239
differentiated 159, 162
diseased 148
lost 157, 159
Neuropathology 183, 194, 229

Neuroprotection 96, 245, 249
Neurotoxicity 90
Neurotransmitters 44, 85, 86, 88,
218, 222
Neurotrophin receptors 157
Neurovascular units 50, 223, 225,
228
NHMRC-ARC dementia research
development fellowship 112
NMDA antagonists 177
Non-steroidal anti-inflammatory
drug (NSAIDs) 63, 64, 65, 98,
100, 101, 103, 113, 186
Nonsteroidal anti-inflammatory
drugs 42, 63
Norepinephrine 44, 182, 218

O

OBNSC, human 157
Octagam 94
Olea europaea 240, 241, 251, 277
Oleocanthal 242, 243, 251, 277
Oleuropein 216, 242, 243, 251, 256,
275, 276, 277

Oleuropein aglycone 243
Olfactory bulbs 155, 156
Oligodendrocytes 155, 156, 157,
158
Oligomers 90, 91, 151, 229
Olive fruits 240, 241
Olive oil 240, 241, 242, 243
Olive trees 240, 241
Onset dementia syndrome 186
Oxidative stress 54, 56, 62, 154,
182, 193, 216, 218, 219, 226,
227, 228, 233, 234, 249

P

Paired-helical filaments (PHF) 146
Parkinson's disease (PD) 60, 103,
104, 184, 188, 243
Passive immunisation 90, 91, 92, 94
Pathology 90, 110, 154, 182
neurodegenerative 90, 182
plaque 110, 154
Pathway 53, 59, 109
disturbed NOS-NO-ADMA 53
inflammatory 59, 109
Patients 6, 12, 15, 95, 179, 185, 189
depression 185
driving abilities 15
self-report 6
experience 179
memory 12
orient 189
variability 95
PBT2-treated patients 106
PD Parkinson's disease 113

Phenolic compounds 233, 241, 242, 253, 274, 275, 277
Piceatannol 230
Pittsburgh compound B (PiB) 106, 113, 194
Plant species natural compounds 251, 252
Polyphenols 220, 229, 230, 233, 239, 242, 278
Pomegranate 233, 234, 260, 265, 267
 extracts 233, 234
 juices 233, 260, 265, 267
Positive predictive value (PPV) 21, 27
Positron electron tomography (PET) 106, 177, 183
Post-mortem brains 59, 96
Postmortem examination 43, 44
Post-op delirium 12
Post-operative delirium 12
Potential benefit of early detection 11, 12, 13, 14
Potentially reversible dementias 15
Presenilin 152, 153, 179, 180, 236
Prodromal stage 44, 193
Pro-inflammatory cytokines 48, 55, 58, 59, 65, 102, 221, 236, 245
Protein-bound metal pools 105
Protein kinase C (PKC) 51, 96, 113
Punica granatum 231, 251, 260, 266, 267, 268, 277
Punica granatum compounds 257, 260
Punicalagin 234, 251, 253, 254, 277

Q

Quercetin 247, 249

R

Reactive nitrogen species (RNS) 54, 228
Reactive oxygen species (ROS) 54, 59, 62, 87, 101, 182, 219, 220, 221, 222, 228, 245
Receiver operating curve (ROC) 22
Receptor antagonists, selective ETA 63
Responses, neuroinflammatory 99
Rhizomes 234, 235, 257
Rivastigmine 18, 86, 188, 194, 195
ROS generation 219, 220
Rosmarinus officinalis 249

S

Salvia miltiorrhiza 243, 244, 245, 252, 268, 269, 277
Salvia officinalis 249, 250
Salvia species 257, 266, 268
SAPP α 87, 89, 91, 95
 neuroprotective 96
SAPP β 89, 91, 96
Screening for dementia 4, 5, 11, 17, 33
Screening tools 4, 5, 7, 27, 33
Secoiridoids 241, 242
Secretase modulators 83, 98, 113, 192

- Secretases 91, 95, 98, 109, 151, 153, 183, 192, 217, 218
Semantic fluency tasks 27, 28
Semantic memory 28, 178
Senile plaques 54, 151, 177, 216, 220, 222
Sensitivity 7, 20, 21, 22, 25, 26, 27, 28, 111, 276
Serum 57, 58, 104
Serum Inflammatory Markers in Dementia Disorders 57
Single nucleotide polymorphisms (SNPs) 95, 113
Skin cancer, non-melanoma 98
Sleep apnea 9, 16
Solanezumab 93, 94
Soluble oligomeric A β species 90
Somatic cells 159, 160, 162
 direct conversion of 160
Sonication 258, 260, 261, 277
Soxhlet extraction 258, 261, 262, 264, 269, 277
Spectrophotometric methods 264, 265, 270, 278
Stem cells 89, 113, 146, 155, 159, 161
 induced pluripotent 113, 146, 159, 161
 neural 89, 146, 155, 156, 161
Stem cells-Therapy 146
Stilbenes 229, 251, 252, 257, 262, 270
Stilbenoids 230, 255
substantia nigra 104, 148, 220, 222
Supportive psychotherapy 189
Symptoms, initial dementia 185
Synaptic cleft 222
Synthase 52, 53
System, cholinergic 85, 86, 88
Systemic inflammation 56, 57
- T**
- Tacrine 86, 87, 188
Tannins 233, 246, 249, 252, 253, 266
Tanshinone II 244
Tanshinones 244, 245, 252, 277
Targets, therapeutic 53, 54, 147
Tau hypothesis 181
Tau protein 63, 177, 183, 184, 217, 218, 227, 229, 230
 hyperphosphorylated 145, 146
Tea 96, 237, 238, 239, 262, 274, 277
 black 238, 239
 green 238, 239, 262, 277
Terpene trilactones 264
Tests 5, 7, 8, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 102, 111, 153, 176, 185, 217
 neurocognitive 176, 185
Tests of executive function 20, 25
Tetrahydrofuran 262, 263, 271
Thalidomide 66
Therapeutic approaches 43, 84, 86, 98, 103, 223
Therapeutic interventions 67, 85, 97, 100, 105, 111
Therapies 91, 97, 98, 189
 reminiscence 189
 targeting 91, 97, 98

- validation 189
 - Thin layer chromatography 262, 265
 - Tissues
 - adipose 49, 50
 - damaged 155, 156
 - TLC 266, 271, 278
 - TNF-alpha 49, 57, 66
 - TNF-R1 227
 - TNF-R2 227
 - Tolerability 93, 98
 - Trans- ϵ -viniferin 255, 257, 261, 270
 - Transforming growth factor (TGF) 221, 223
 - Transitional stage 193, 194
 - Transplantation 157, 158
 - Transport, axonal 218
 - Trans-resveratrol 255, 257
 - Treatment 5, 44, 63, 67, 87, 111, 176, 248
 - disease-modifying 111
 - earlier 5, 44
 - effective 67, 176
 - nicotine 87
 - symptomatic 63, 248
 - Treatment effects 16, 93, 95, 111
 - Treatment group 20, 106, 192
 - Treatment modalities 192, 195
 - studied 195
 - Triterpenes 241, 252, 256
 - Tropomyosin receptor kinase A (TRKA) 157
 - Troupin 32
 - Tumor necrosis factor (TNF α) 48, 58, 65, 101, 114, 181, 220, 221, 223, 224, 227
 - Turmeric 102, 234, 235, 236, 237
 - Turmerone 235, 237
 - Tyrosol 242, 243, 251
- U**
- Ultrasonication 260
- V**
- Vascular 28, 41, 44, 45, 46, 50, 52, 53, 55, 57, 61, 63, 156, 182, 215, 216, 217, 224
 - aging 52
 - cognitive impairment (VCI) 28, 50
 - dementia 44, 55, 57, 61
 - dementia
 - hyperhomocysteinemia-induced 63
 - dysfunction 52
 - endothelial growth factor (VEGF) 156, 224
 - endothelial growth receptor (VEGR) 224
 - insufficiency 55
 - risk factors 41, 45, 46, 48, 53, 55, 182
 - products 215, 216, 217
 - Verbascoside 242
 - Verubecestat 91, 97
 - Vitis vinifera* 228, 230, 251, 277
- Z**
- Zn and Fe levels 104



PROF. DR. ATTA-UR-RAHMAN, *FRS*

Prof. Atta-ur-Rahman obtained his Ph.D. in organic chemistry from Cambridge University (1968). He has 974 publications in several fields of organic chemistry including 718 research publications, 37 international patents, 151 books and 68 chapters in books published largely by major U.S. and European presses. He is the Editor-in-Chief of several European Chemistry journals and the Editor of "Studies in Natural Product Chemistry" 50 volumes of which have been published by Elsevier Science Publishers (Netherlands) under his Editorship during the last two decades. Eighty students have completed their Ph.D. degrees under his supervision.

Prof. Rahman was elected Fellow of Royal Society (London) (2006) and won the UNESCO Science Prize (1999). He has been conferred honorary doctorate degrees by Cambridge University and many other universities. He was elected Honorary Life Fellow of Kings College, Cambridge University (2007).